

# Life Sciences

---

Our cross-border, multidisciplinary team brings unique market awareness and a business-minded approach to players in the life sciences industry.



## Overview

---

Torys' Life Sciences practice is the only Canadian practice to be consistently ranked in Band 1 by Chambers and Partners and is recognized for transactional strength and broad IP capabilities. Our team includes over 40 lawyers and patent agents, including PhDs, MScs and engineers. It is this sophisticated capability that facilitates the pragmatic and innovative counsel we give to clients across the life sciences ecosystem.

We serve biotech, pharmaceutical, medical device and health technology companies on all aspects of their business. With full-service capabilities on both sides of the Canada-U.S. border, we are uniquely positioned to advise organizations as a single firm on cross-border transactions.

#### PRIMARY CONTACT



**Eileen M. McMahon**

## Areas of Service

---

### Intellectual Property

We advise on the protection and commercial exploitation of IP rights, and ongoing management of patents and trademarks, including those related to the collection and use of data, diagnostics and other pharma-related services.

### Food and Drug

Our team regularly advises on regulatory compliance and marketing, including advertising and pricing matters, *Food and Drugs Act* compliance, trade, pricing, and cross-border digital sales issues.

### M&A

Our leading M&A team provides multidisciplinary, sophisticated advice in the sector's most complex and significant transactions, domestically and internationally.

### Capital Markets

We give clients tailored solutions to access the capital markets on both sides of the Canada-U.S. border, offering an integrated, one-firm approach to domestic and cross-border offerings.

### Emerging Companies and VC

We help life sciences startups to protect inventions, commercialize, and establish business structures. We also assist with their licensing, financing and M&A work, and help investors in the sector realize their investment strategies.

### Intellectual Property Litigation

Our team partners with clients in protecting, enforcing and licensing IP rights, including patents. We manage complex matters, acting for clients in disputes before all levels of courts, IP tribunals and regulatory bodies.

### Pharma and Biotech

We advise on regulatory, privacy and pricing issues; drafting and negotiating agreements; consents for both the use of data or biological materials in research and for clinical trials; and product approvals and product launches.

### Cannabis

We have broad experience in the cannabis ecosystem—from compliance, production and IP advice, to financing, M&A and governance. Our clients span the sector and include licensed producers, researchers and developers.

We are recognized for *exceptional depth* of industry experience and uncompromising client service for all players in the sector.

> \$1B

Series A financings in the last three years

**We know how to drive growth.**

We help emerging companies scale and thrive. We have advised on Series A financings totaling over \$1B in the last three years.

**We work with industry leaders.**

Our cross-border team is longstanding counsel to 14 of the world's top 20 medical device companies, and 17 of the world's top 20 pharmaceutical companies.

17/20

Top pharma companies

14/20

Top medical devices companies

## Featured Work

### Launch of OmniaBio

Torys acted as counsel to OmniaBio in connection with its launch, including its spinout from the Centre for Commercialization of Regenerative Medicine (CCRM), its C\$30 million sale of a 39.6% interest to Medipost Co. Ltd., C\$40 million in government funding by the Government of Ontario, and up to C\$100 million convertible note financing with CCRM and Medipost, and the negotiation of its leasing arrangements for a new C\$580 million state-of-the-art cell and gene therapy facility at MacMaster Innovation Park in Hamilton, Ontario

### Made-in-Canada vaccines

Torys acted as strategic advisor to the Government of Canada in its agreement with Moderna, Inc. to establish a state-of-the-art mRNA vaccine manufacturing facility in Québec, supporting the development and production of vaccines for COVID-19 and other respiratory diseases in Canada

[Read More](#)

# Representative Work

---

## **Treatment.com AI to acquire Rocket Doctor**

Rocket Doctor in its sale to Treatment.com AI Inc., the developer of a comprehensive, personalized healthcare engine leveraging artificial intelligence and best clinical practices to positively improve patient care

## **Endo to sell its international pharmaceuticals business**

Endo in the proposed sale of its international pharmaceuticals business, primarily operated through Paladin Pharma Inc., to Knight Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, licensing and marketing innovative prescription pharmaceuticals in Canada and Latin America

## **Fengate and eMAX Health announce partnership to drive innovation in healthcare technology**

Fengate in its investment in eMAX Health, a leading provider of independent research to pharmaceutical companies and innovative pharmaceutical distribution support

## **Mérieux NutriSciences completes acquisition of worldwide food testing business**

Mérieux NutriSciences, as Canadian counsel, in its acquisition of the food testing business of Bureau Veritas SA

## **Med Learning Group acquires Throughline**

Med Learning Group in its acquisition of Throughline Strategy Inc., an applied insights and strategy consulting firm for organizations in the healthcare ecosystem

## **Sienna completes C\$150 million offering of Series D senior unsecured debentures**

Sienna Senior Living in its C\$150 million private placement of 4.436% senior unsecured debentures, Series D

## **Sienna Senior Living completes C\$144 million public equity offering**

Sienna Senior Living in its C\$144 million public offering of common shares

## **Neuronetics and Greenbrook TMS close merger**

Greenbrook TMS in its all-stock merger with Neuronetics, Inc. to create a vertically integrated organization capable of providing TMS therapy at scale

## **a private equity firm in its acquisition of an international research organization in the health sciences space**

Catalyst Pharmaceuticals in its commercial agreement with Kye Pharmaceuticals Inc., granting Kye the exclusive Canadian commercial rights to AGAMREE® (vamorolone), a novel corticosteroid for the treatment of Duchenne Muscular Dystrophy



They're very experienced in the biopharmaceuticals and healthcare area and we get a very tailored service. They always deliver results, no matter how tight the timeline is.

— CHAMBERS CANADA, 2023

## Latest Insights

---

### 12th Annual Summit for Women Leaders in Life Sciences Law

Partner Yael Bienenstock will speak on the panel “Collaborate to Innovate: Mastering the Legal and Business Complexities of Life Sciences Industry Partnerships and Alliances” on July 30 at 2:30 p.m.

[Read More](#)

### Health Canada to modernize biologic drug submissions

Proposed new guidance from Health Canada aims to streamline submissions for biosimilar and innovative biologic drugs.

[Read More](#)

### Final Guidelines from Canada's PMPRB: the new era begins

The PMPRB's final Guidelines build on interim guidance adopted in 2023 and will come into effect in January 2026.

[Read More](#)

### Psychedelic appeal: FCA rules that government must explain policy change on psilocybin access

Policy decisions that conflict with a regulator's prior determination must be justified—or otherwise be vulnerable to judicial review.

[Read More](#)

### 2nd Annual Summit on PFAS Regulation, Compliance and Litigation

Partner and co-chair of our national product liability practice group Grant Worden will speak on the panel “International Outlook on PFAS: Contrasting Developments in Canada, the EU, and Beyond” on May 30 at 2:30 p.m.

[Read More](#)

## Mental Health Awareness for Legal Professionals

Partner and Chair of Torys' Intellectual Property and Food and Drug Regulatory practices Eileen McMahon will moderate the Intellectual Property Institute of Canada webinar "Mental Health Awareness for Legal Professionals" taking place on May 5 at 1:00 p.m.

[Read More](#)

## Recent Recognition

---

[Band 1 in Life Sciences \(Chambers Canada\)](#)

[Regulatory Firm of the Year—Canada by LMG Life Sciences \(2024\)](#)

[Eileen McMahon named leading IP practitioner by Managing IP \(2025\)](#)

[Sylvie Rodrigue named 2022 Canadian Product Liability Attorney of the Year \(LMG Life Sciences Americas\)](#)

[IP and Life Sciences Law Firm of the Year 2023 \(Chambers Canada\)](#)

## Recent News

---

### Torys' strength in patent law recognized by *Managing IP*

Among those ranked, partner Eileen McMahon was named one of 2025's Top 250 Women in IP for the ninth consecutive year.

[Read More](#)

### *Lexpert* names Leah Frank and Nicole Mantini 2024 Rising Stars

[Read More](#)

### 81% of Torys' Canadian partners ranked by *Chambers Canada*

[Read More](#)

### Torys receives three accolades at the 2024 *LMG Life Sciences Americas Awards*

The firm was awarded Regulatory Firm of the Year and Impact Deal of the Year, and partner Eileen McMahon was named Regulatory Attorney of the Year.

[Read More](#)

### *Benchmark Litigation* names three Torys lawyers in 40 and Under list

Congratulations to partners Nicole Mantini, Jeremy Opolsky and Sarah Whitmore.

[Read More](#)

## Torys named Law Firm of the Year at the 2024 *IFLR Americas* Awards

Torys was also awarded the Tech Innovation Award for our Side Letter Management Tool.

[Read More](#)

## Related Services

---

→ [Agribusiness](#)

→ [Consumer and Retail](#)